Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 known ✓ | P25103 | 4/20 | 0.61 |
| ▸ | HTR2A known ✓ | P28223 | 2/20 | 0.55 |
| ▸ | ADRB1 known ✓ | P08588 | 1/20 | 0.55 |
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.55 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.55 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.55 |
| ▸ | HTR1D known ✓ | P28221 | 1/20 | 0.55 |
| ▸ | HTR1B known ✓ | P28222 | 1/20 | 0.55 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.55 |
| ▸ | HTR1E known ✓ | P28566 | 1/20 | 0.55 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.55 |
| ▸ | HTR7 known ✓ | P34969 | 1/20 | 0.55 |
| ▸ | HTR2B known ✓ | P41595 | 1/20 | 0.55 |
| ▸ | HTR6 known ✓ | P50406 | 1/20 | 0.55 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.55 |
| ▸ | ACE known ✓ | P12821 | 1/20 | 0.49 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3954521 | 1.00 | MAPT (0.64) | MAPTKDM4EMEN1LMNAMPO | |
| SCHEMBL30406357 | 0.99 | MAPT (0.65) | MAPTKDM4EMEN1LMNAMPO | |
| SCHEMBL21309637 | 0.99 | MAPT (0.65) | MAPTKDM4EMEN1LMNAMPO | |
| SCHEMBL29498785 | 0.99 | MAPT (0.65) | MAPTKDM4EMEN1LMNAMPO | |
| SCHEMBL7775097 | 0.99 | MAPT (0.65) | MAPTKDM4EMEN1LMNAMPO | |
| SCHEMBL594511 | 0.99 | MAPT (0.65) | MAPTKDM4EMEN1LMNAMPO | |
| SCHEMBL11771081 | 0.89 | MAPT (0.60) | MAPTKDM4EMEN1LMNAMPO | |
| SCHEMBL10383061 | 0.88 | MAPT (0.64) | MAPTKDM4EMEN1LMNAMPO | |
| SCHEMBL24786009 | 0.87 | KDM4E (0.60) | MAPTKDM4EMEN1LMNAMPO | |
| SCHEMBL13402573 | 0.86 | MAPT (0.62) | MAPTKDM4EMEN1LMNAMPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023240103-A1 | ANTIMICROBIAL COMPOSITION | THE PROCTER & GAMBLE COMPANY (US) | 2023-12-14 | — | — | WO | disclosed |
| EP-4289269-A1 | ANTIMICROBIAL COMPOSITION | The Procter & Gamble Company (US) | 2023-12-13 | — | — | EP | disclosed |
| US-20230389545-A1 | ANTIMICROBIAL COMPOSITION | THE PROCTER & GAMBLE COMPANY | 2023-12-07 | — | — | US | disclosed |
| EP-3601224-B1 | CHEMICAL COMPOUNDS AS ANTIBIOTICS | ANTABIO SAS (FR) | 2023-07-05 | — | — | EP | disclosed |
| CN-110914238-B | Compounds as antibiotics | 安塔比奥公司 | 2023-06-20 | — | — | CN | disclosed |
| US-11000511-B2 | Chemical compounds as antibiotics | ANTABIO SAS (FR) | 2021-05-11 | — | — | US | disclosed |
| CN-107106449-B | Use of ester derivatives of tryptophan as deodorants and/or odorants | 欧莱雅 | 2020-12-11 | — | — | CN | disclosed |
| US-20200155509-A1 | CHEMICAL COMPOUNDS AS ANTIBIOTICS | ANTABIO SAS (FR) | 2020-05-21 | — | — | US | disclosed |
| CN-110914238-A | Compounds as antibiotics | 安塔比奥公司 | 2020-03-24 | — | — | CN | disclosed |
| CN-107106449-A | The ester derivant of tryptophan as deodorant and/or flavouring agent purposes | 欧莱雅 | 2017-08-29 | — | — | CN | disclosed |
| CN-100480248-C | Malonamide derivatives as gamma-secretase inhibitors | HOFFMANN LA ROCHE (CH) | 2009-04-22 | — | — | CN | disclosed |
| CN-101228123-A | Novel 2-azetidinone derivatives and their use as cholesterol absorption inhibitors for the treatment of hyperlipidaemia | ASTRAZENECA AB (SE) | 2008-07-23 | — | — | CN | disclosed |
| CN-101065354-A | Diphenylazetidinone derivates possessing cholesterol absorption inhibitory activity | ASTRAZENECA AB (SE) | 2007-10-31 | — | — | CN | disclosed |
| CN-1745076-A | Malonamide derivatives as gamma-secretase inhibitors | HOFFMANN LA ROCHE (CH) | 2006-03-08 | — | — | CN | disclosed |
| US-6500842-B1 | N-((4-CHLOROPHENYL)METHYL)-8-HYDROXY-7-QUINOLINECARBOXAMIDE ADMINISTERED AS VIRICIDES AGAINST HERPES VIRUS | PHARMACIA & UPJOHN COMPANY | 2002-12-31 | — | — | US | disclosed |
| US-6310211-B1 | ANTI-VIRAL ACTIVITY AGAINST HERPES VIRUS, CYTOMEGALOVIRUS. MANY OF THESE COMPOUNDS ARE ALSO ACTIVE AGAINST VARICELLA ZOSTER VIRUS, EPSTEIN-BARR VIRUS, HERPES SIMPLEX VIRUS AND HUMAN HERPES VIRUS TYPE 8 | PHARMACIA & UPJOHN COMPANY | 2001-10-30 | — | — | US | disclosed |
| US-6252080-B1 | HERPES, CYTOMEGALO VIRUS | PHARMACIA & UPJOHN COMPANY | 2001-06-26 | — | — | US | disclosed |
| US-6211376-B1 | HERPES VIRUS, CYTOMEGALO VIRUS, VARICELLA-ZOSTER VIRUS,EPSTEIN-BARR VIRUS | PHARMACIA & UPJOHN COMPANY | 2001-04-03 | — | — | US | disclosed |
| EP-0927164-A1 | 8-HYDROXY-7-SUBSTITUTED QUINOLINES AS ANTI-VIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 1999-07-07 | — | — | EP | disclosed |
| WO-1998011073-A1 | 8-HYDROXY-7-SUBSTITUTED QUINOLINES AS ANTI-VIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 1998-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200155509-A1 | CHEMICAL COMPOUNDS AS ANTIBIOTICS | MRPL21, CFTR, H1-0 | TACR1 471/4885HTR2A 4475/4885ADRB1 2515/4885 |
| US-20230389545-A1 | ANTIMICROBIAL COMPOSITION | ARG1, CUTA, AAAS | TACR1 4197/4885HTR2A 4055/4885ADRB1 2678/4885 |
| US-11000511-B2 | Chemical compounds as antibiotics | MRPL21, CFTR, H1-0 | TACR1 471/4885HTR2A 4475/4885ADRB1 2515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.